TITOMIC
1.7.2020 09:32:08 CEST | Business Wire | Press release
The inaugural CEO of Saudi Arabian Military Industries (SAMI), Dr Andreas Schwer, has been appointed Chairman of the Melbourne-based industrial-scale additive manufacturing company Titomic (ASX:TTT) www.titomic.com .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701005306/en/
Beginning immediately, Dr Schwer, who boasts a 25-year career in the global defence, manufacturing, and aerospace industries will bring a wealth of experience to Titomic. The news comes just days after Titomic announced the appointments of Mr Dag W.R. Stromme, a former Managing Director of Morgan Stanley; and Mr Humphrey Nolan, an experienced leader in the global industrial and distribution industries.
As the first CEO at SAMI, which was established in 2017, Dr Schwer led this greenfield operation to become a multi-billion-dollar company in 2020 before recently stepping down.
Prior to his role at SAMI, Dr Schwer was Chairman and President of Rheinmetall International - Rheinmetall AG. Dr Schwer also held roles including CEO of Combat Systems & Executive Board Member of Rheinmetall Defence overseeing the units of Combat Platforms, Weapons & Munitions, Protection Systems, and Propulsion Systems. Dr Schwer also holds 12 years’ experience at Airbus in executive roles across the Defence & Space and Helicopter divisions.
Titomic’s Managing Director and Founder, Mr. Jeff Lang, said: “Andreas’ extensive professional experience in the global defence and aerospace sectors facilitates strong opportunities for Titomic to become a dominant player in the USD$4 trillion metals manufacturing industry for a green-tech future.”
Further, Dr Schwer stated; “I am honoured to accept the role of Chairman at Titomic and look forward to leading the Company to capitalise on its considerable opportunities and further add shareholder value. I believe Titomic’s industrial scale metal additive manufacturing and sustainable, green technology has tremendous commercial potential to take metal manufacturing industries into the future.”
Dr Schwer has a Dipl.-Ing in Aerospace Engineering and a PhD in System Modelling and Numerical Optimisation, both from the University of Stuttgart, and a Master of Science in System-Engineering from TU Delfi (The Netherlands).
Dr Schwer says he’s delighted to be joining the Board of a company that’s starting to make its presence felt globally, as demonstrated by the sale of two Titomic Kinetic Fusion® systems to a global defence manufacturer, as well as reaching agreements with companies of the calibre of Boeing, Airbus, and Thales.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200701005306/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release
Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom